A comparison of the ability of the human IgG1 allotypes G1m3 and G1m1,17 to stimulate T-cell responses from allotype matched and mismatched donors

mAbs

Volumn 8, Issue 2, 2016, Pages 253-263

  Webster, Carl I ^a   Bryson, Christine J ^b   Cloake, Edward A ^b   Jones, Tim D ^b   Austin, Mark J ^a   Karle, Anette C ^c   Spindeldreher, Sebastian ^c   Lowe, David C ^a   Baker, Matthew P ^b  

^a MEDIMMUNE   (United States)

^b Antitope Ltd   (United Kingdom)

^c NOVARTIS PHARMA AG   (Switzerland)

Author keywords

Allotype; Epitope; HLA; IgG; Immunogenicity; MAPPs; MHC; T cell

Indexed keywords

B7 ANTIGEN; CD40 ANTIGEN; CD83 ANTIGEN; CD86 ANTIGEN; GLYCOPROTEIN P 15095; HLA DR ANTIGEN; IMMUNOGLOBULIN ALLOTYPE; IMMUNOGLOBULIN G1; IMMUNOGLOBULIN G1 M1; IMMUNOGLOBULIN G1 M17; IMMUNOGLOBULIN G1 M3; INTERLEUKIN 2; TRASTUZUMAB; UNCLASSIFIED DRUG; IMMUNOGLOBULIN G;

ARTICLE; BLOOD BUFFY COAT; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL PROLIFERATION; CELL PROLIFERATION ASSAY; CHROMATOGRAPHY; CONTROLLED STUDY; DONOR; ENZYME LINKED IMMUNOSPOT ASSAY; EPITOPE MAPPING; GENE AMPLIFICATION; GENETIC VARIATION; HLA SYSTEM; HUMAN; HUMAN CELL; IMMUNOGENICITY; IMMUNOPRECIPITATION; MAJOR CLINICAL STUDY; NORMAL HUMAN; POLYMERASE CHAIN REACTION; PROTEOMICS; REVERSED PHASE HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; SEQUENCE ANALYSIS; T LYMPHOCYTE ACTIVATION; BLOOD DONOR; COMPARATIVE STUDY; FEMALE; IMMUNOLOGY;

BLOOD DONORS; CD4-POSITIVE T-LYMPHOCYTES; FEMALE; HLA-DR ANTIGENS; HUMANS; IMMUNOGLOBULIN G; IMMUNOGLOBULIN GM ALLOTYPES;

EID: 84964489760     PISSN: 19420862     EISSN: 19420870     Source Type: Journal    
DOI: 10.1080/19420862.2015.1128605     Document Type: Article

References (37)

1. KohlerG, MilsteinC.Continuous cultures of fused cells secreting antibody of predefined specificity. Nature1975; 256:495-7; PMID:1172191; http://dx.doi.org/10.1038/256495a0
2. RiechmannL, ClarkM, WaldmannH, WinterG.Reshaping human antibodies for therapy. Nature1988; 332:323-7; PMID:3127726; http://dx.doi.org/10.1038/332323a0
3. JonesPT, DearPH, FooteJ, NeubergerMS, WinterG.Replacing the complementarity-determining regions in a human antibody with those from a mouse. Nature1986; 321:522-5; PMID:3713831; http://dx.doi.org/10.1038/321522a0
4. McCaffertyJ, GriffithsAD, WinterG, ChiswellDJ.Phage antibodies: Filamentous phage displaying antibody variable domains. Nature1990; 348:552-4; PMID:2247164; http://dx.doi.org/10.1038/348552a0
5. LonbergN.Human antibodies from transgenic animals. Nat Biotechnol2005; 23:1117-25; PMID:16151405; http://dx.doi.org/10.1038/nbt1135
6. MorrisonSL, JohnsonMJ, HerzenbergLA, OiVT.Chimeric human antibody molecules: Mouse antigen-βinding domains with human constant region domains. Proc Natl Acad Sci U S A1984; 81:6851-5; PMID:6436822; http://dx.doi.org/10.1073/pnas.81.21.6851
7. ReichertJM, Valge-ArcherVE.Development trends for monoclonal antibody cancer therapeutics. Nat Rev Drug Dis2007; 6:349-56; PMID:17431406; http://dx.doi.org/10.1038/nrd2241
8. HwangYKH, and FooteJ.Immunogenicity of engineered antibodies. Methods2005; 36:3-10; PMID:15848070; http://dx.doi.org/10.1016/j.ymeth.2005.01.001
9. HardingFA, SticklerMM, RazoJ, DuBridgeRB.The immunogenicity of humanized and fully human antibodies: Residual immunogenicity resides in the CDR regions. mAbs2010; 2:256-65; PMID:20400861; http://dx.doi.org/10.4161/mabs.2.3.11641
10. JefferisR, LefrancMP, Human immunoglobulin allotypes: Possible implications for immunogenicity. mAbs2009; 1:332-8; PMID:20073133; http://dx.doi.org/10.4161/mabs.1.4.9122
11. GrubbR, Reaction of rheumatoid arthritic sera with a human antibody gamma globulin. Acta Rheumatol Scand1956; 2:55-8; PMID:13424354; http://dx.doi.org/10.3109/rhe1.1956.2.issue-1-4.07
12. AllenJC, KunkelHG.. Antibodies to genetic types of gamma globulin after multiple transfusions. Science1963; 139:418-9; PMID:14012122; http://dx.doi.org/10.1126/science.139.3553.418
13. SteinbergAg, WilsonJa. Hereditary globulin factors and immune tolerance in man. Science1963; 140:303-4; PMID:13983708; http://dx.doi.org/10.1126/science.140.3564.303
14. FudenbergHH., FudenbergBR.Antibody to hereditary human gamma-globulin (gm) factor resulting from maternal-fetal incompatibility. Science1964; 145:170-1; PMID:14171557; http://dx.doi.org/10.1126/science.145.3628.170
15. OudinJ.[The allotype of certain blood protein antigens]. C R Hebd Seances Acad Sci1956; 242:2606-8; PMID:13343562
16. de LangeGG.Polymorphisms of human immunoglobulins: Gm, Am, Em and Km allotypes. Exp Clin Immunogen1989; 6:7-17; PMID:2698222
17. WHO. Review of the notation for the allotypic and related markers of human immunoglogulins. J Immunol1976; 117:1056-8; PMID:956649
18. ChanAC, &CarterPJ.Therapeutic antibodies for autoimmunity and inflammation. Nat Rev Immunol2010; 10:301-16; PMID:20414204; http://dx.doi.org/10.1038/nri2761
19. MeltzerM, FranklinEC, FundenbergH, FrangioneB.Signal peptide differences between gamma-globulins of different genetic (gm) types. Proc Natl Acad Sci U S A1964; 51:1007-14; PMID:14218064; http://dx.doi.org/10.1073/pnas.51.6.1007
20. Frangione, B., FranklinEC, FudenbergHH, and KoshlandME.Structural studies of human gamma-G-myeloma proteins of different antigenic subgroups and genetic specificities. J Exp Med1966; 124:715-32; PMID:4162448; http://dx.doi.org/10.1084/jem.124.4.715
21. PressEM, HoggNM.The amino acid sequences of the fd fragments of two human gamma-1 heavy chains. Biochem J1970; 117:641-60; PMID:5449120; http://dx.doi.org/10.1042/bj1170641
22. JohnsonWE, KohnPH, SteinbergAG.Population genetics of the human allotypes Gm, Inv, and A2m. Clin Immunol Immunopathol1977; 7:97-113; PMID:404106; http://dx.doi.org/10.1016/0090-1229(77)90034-4
23. Magdelaine-βeuzelinC, VermeireS, GoodallM, BaertF, NomanM, AsscheGV, OhresserM, DegenneD, DugoujonJM, JefferisR, et al.IgG1 heavy chain-coding gene polymorphism (G1m allotypes) and development of antibodies-to-infliximab. Pharmacogen Gen2009; 19:383-7; PMID:19319024; http://dx.doi.org/10.1097/FPC.0b013e32832a06bf
24. BarteldsGM, de GrootE, NurmohamedMT, HartMHL, van EedePH, WijbrandtsCA, CrusiusJBA, DijkmansBAC, TakPP, AardenL, WolbinkGJ, Surprising negative association between IgG1 allotype disparity and anti-adalimumab formation: A cohort study. Arthritis Res Ther2010; 12:221; PMID:21187010; http://dx.doi.org/10.1186/ar3208
25. BakerMP, JonesTD.Identification and removal of immunogenicity in therapeutic proteins. Curr Opin Drug Discov Devel2007; 10:219-27; PMID:17436557
26. KropshoferH, SpindeldreherS, RohnTA, PlataniaN, GrygarC, DanielN, WolplA, LangenH, HorejsiV, VogtAB.Tetraspan microdomains distinct from lipid rafts enrich select peptide-MHC class II complexes. Nat Immunol2002; 3:61-8; PMID:11743588; http://dx.doi.org/10.1038/ni750
27. Rombach-RiegrafV, KarleAC, WolfB, SordeL, KoepkeS, GottliebS, KriegJ, DjidjaMC, BabanA, SpindeldreherS, et al.Aggregation of human recombinant monoclonal antibodies influences the capacity of dendritic cells to stimulate adaptive T-cell responses in vitro. PLoS One [Electronic Resource]2014; 9:e86322; PMID:24466023; http://dx.doi.org/10.1371/journal.pone.0086322
28. RohnTA, ReitzA, PaschenA, NguyenXD, SchadendorfD, VogtAB, KropshoferH. Anovel strategy for the discovery of MHC class IIrestricted tumor antigens: Identification of a melanotransferrin helper T-cell epitope. Cancer Res2005; 65:10068-78; PMID:16267033; http://dx.doi.org/10.1158/0008-5472.CAN-05-1973
29. BarkerS.Immunogenicity of biotherapeutics: A need for consensus on flexibility of approach. Curr Drug Safety2010; 5:272-4; PMID:20925649; http://dx.doi.org/10.2174/157488610792245975
30. KropshoferH, SingerT.Overview of cell-βased tools for pre-clinical assessment of immunogenicity of biotherapeutics. J Immunotoxicol2006; 3:131-6; PMID:18958693; http://dx.doi.org/10.1080/15476910600845625
31. PerryLC, JonesTD, BakerMP.New approaches to prediction of immune responses to therapeutic proteins during preclinical development. Drugs in R & D2008; 9:385-96; PMID:18989990; http://dx.doi.org/10.2165/0126839-200809060-00004
32. SticklerMM, ReddyA, XiongJM, HintonPR, DuBridgeR, HardingFA.The human G1m1 allotype associates with CD4C T-cell responsiveness to a highly conserved IgG1 constant region peptide and confers an asparaginyl endopeptidase cleavage site. Gene Immunity2011; 12:213-21; PMID:21326320; http://dx.doi.org/10.1038/gene.2010.68
33. Carter, P., Presta, L., GormanCM, RidgwayJBB, Henner, D., WongWLT, RowlandAM., Kotts, C., CarverME, ShepardHM.,. Humanization of an anti-p185HER2 antibody for human cancer therapy. Proe Natl Acad Sc USA1992; 89:4285-9; PMID:1350088; http://dx.doi.org/10.1073/pnas.89.10.4285
34. PersicL, RobertsA, WiltonJ, CattaneoA, BradburyA, HoogenboomHR.An integrated vector system for the eukaryotic expression of antibodies or their fragments after selection from phage display libraries. Gene1997; 187:9-18; PMID:9073061; http://dx.doi.org/10.1016/ S0378-1119(96)00628-2
35. JonesTD, PhillipsWJ, SmithBJ, BamfordCA, NayeePD, BaglinTP, GastonJS, BakerMP.Identification and removal of a promiscuous CD4C T cell epitope from the C1 domain of factor VIII. J Thromb Haemostasis2005; 3:991-1000; PMID:15869596; http://dx.doi.org/10.1111/j.1538-7836.2005.01309.x
36. LefrancMP, PommieC, KaasQ, DupratE, BoscN, GuiraudouD, JeanC, RuizM, Da PiedadeI, RouardM, et al.IMGT unique numbering for immunoglobulin and T cell receptor constant domains and Ig superfamily C-like domains. Dev Comp Immunol2005; 29:185-203; PMID:15572068; http://dx.doi.org/10.1016/j.dci.2004.07.003
37. Lefranc, G., Lefranc, M.-P.The Immunoglobulin Factsbook. London: Academic Press, 2001.